We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) , along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx (tablet formulation of cabozantinib) at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
The trial compared Cabometyx with Afinitor in patients suffering from advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
Data from the studies showed that treatment with Cabometyx improved progression-free survival (PFS) and overall survival (OS) in patients who had bone metastases at baseline.
Trial data also showed that the benefits of Cabometyx in PFS and OS were independent of the presence of bone metastases, prior anti-PD-1/PD-L1 therapy, and the type of prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. They were, in fact, consistent regardless of prior treatment, location and extent of tumor metastases.
Shares of the company gained 11.2% on the news.
We remind investors that Cabometyx was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.
The FDA approval of Cabometyx for RCC is a major boost for the company and will drive the top line in the forthcoming quarters.
Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Ipsen. The MAA was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates to a review period of 150 days instead of the standard review period of 210 days.
Cometriq, the capsule form of cabozantinib is approved for the treatment of progressive, metastatic medullary thyroid cancer.
Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pfizer Inc. (PFE - Free Report) , Johnson & Johnson (JNJ - Free Report) and Abbott Laboratories (ABT - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson and Abbott Labs carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Exelixis, Inc. (EXEL - Free Report) , along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx (tablet formulation of cabozantinib) at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
The trial compared Cabometyx with Afinitor in patients suffering from advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
Data from the studies showed that treatment with Cabometyx improved progression-free survival (PFS) and overall survival (OS) in patients who had bone metastases at baseline.
Trial data also showed that the benefits of Cabometyx in PFS and OS were independent of the presence of bone metastases, prior anti-PD-1/PD-L1 therapy, and the type of prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. They were, in fact, consistent regardless of prior treatment, location and extent of tumor metastases.
Shares of the company gained 11.2% on the news.
We remind investors that Cabometyx was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.
The FDA approval of Cabometyx for RCC is a major boost for the company and will drive the top line in the forthcoming quarters.
Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Ipsen. The MAA was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates to a review period of 150 days instead of the standard review period of 210 days.
Cometriq, the capsule form of cabozantinib is approved for the treatment of progressive, metastatic medullary thyroid cancer.
Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pfizer Inc. (PFE - Free Report) , Johnson & Johnson (JNJ - Free Report) and Abbott Laboratories (ABT - Free Report) . While Pfizer sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson and Abbott Labs carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>